Why the study?
Does tofogliflozin reduce the progression of carotid intima-media thickness in Japanese patients with type 2 diabetes without a history of cardiovascular disease?
Population
340 Japanese patients with type 2 diabetes and inadequate glycemic control, aged 30-74 years, with no…
Comparison
Tofogliflozin 20 mg orally once daily. vs Conventional treatment using anti-diabetic drugs…
Design
RCT, 1:1 randomization using a dynamic allocation method based on insulin…
Follow-up
104 weeks
Authors
Loading...
Will establish whether SGLT2 inhibition directly modifies atherosclerotic progression in primary prevention; leaves open.
Does tofogliflozin reduce the progression of carotid intima-media thickness in Japanese patients with type 2 diabetes without a history of cardiovascular disease?
The UTOPIA trial is designed to evaluate whether the SGLT2 inhibitor tofogliflozin prevents the progression of carotid intima-media thickness, a surrogate marker of atherosclerosis, in patients with type 2 diabetes without a history of cardiovascular disease.
Katakami et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: